-+ 0.00%
-+ 0.00%
-+ 0.00%

Hualing Pharmaceutical announced that the company's second-generation glucokinase activator HMS1005 was successfully administered to the first patient in the multi-dose incremental phase Ib trial conducted in the US. The study was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamic effects of multi-dose escalated HMS1005 in American subjects with type 2 diabetes. At the same time, the study will further explore the mechanism and effects of HMS1005 by evaluating PD markers on an empty stomach and when eating and monitoring blood sugar fluctuations through continuous blood sugar monitors.

Zhitongcaijing·12/09/2025 11:49:20
Listen to the news
Hualing Pharmaceutical announced that the company's second-generation glucokinase activator HMS1005 was successfully administered to the first patient in the multi-dose incremental phase Ib trial conducted in the US. The study was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamic effects of multi-dose escalated HMS1005 in American subjects with type 2 diabetes. At the same time, the study will further explore the mechanism and effects of HMS1005 by evaluating PD markers on an empty stomach and when eating and monitoring blood sugar fluctuations through continuous blood sugar monitors.